Friday, June 9, 2017

TissuGlu® Surgical Adhesive enables drain-free recovery in patients undergoing DIEP flap breast reconstruction

RALEIGH, N.C., June 08, 2017 -- Outcomes of the SANA Gerresheim series demonstrated that effective donor-site flap closure with TissuGlu Surgical Adhesive is a viable alternative to post-surgical drains.  Dr. Sonia Fertsch presented the series, which included 41 DIEP flap breast reconstructions, at the EURAPS Research Council Meeting in Pisa last month. The annual event allows young surgeons to present top research initiatives to an audience of plastic surgeons and researchers from around the world. 
During a DIEP flap reconstruction, blood vessels, skin and fat of the lower abdomen are removed and utilized to reconstruct a breast following mastectomy.  The technique is widely recognized as the top option for autologous tissue breast reconstruction, but typically requires the use of several surgical drains at the donor site during recovery.  Drains may cause discomfort, anxiety and limited mobility during recovery and are often a deterrent for patients when considering treatment options.
The Department of Plastic Surgery at the SANA Clinic in Gerresheim, Germany, headed up by Prof. Christoph Andree, is a top center for reconstruction and performs approximately 200 DIEP procedures per year. The group, dedicated to improving recovery and acceptance of DIEP flap reconstructions, began evaluating TissuGlu® Surgical Adhesive in 2015 with hopes it would enable drain-free donor site recovery.
“The choice of using a patient’s own tissue for breast reconstruction has clear benefits with respect to implant based reconstruction, and patients who are candidates for DIEP flap-based reconstruction appreciate the reduction in abdominal skin and fatty tissue,” says Prof. Christoph Andree. “Being able to offer this procedure without the use of donor site drains improves the patient experience in the early recovery period and leads to earlier mobilization – one of the key milestones in postoperative recovery.” 
Dr. Fertsch, who led the observational series, said: “Many of our patients have had experience with post-surgical drains in the past and they are very enthusiastic about the possibility that they may be able to avoid having them as part of the DIEP flap breast reconstruction procedure. It is not for all patients, but it is a welcome option for those who meet the criteria we have developed based on our clinical outcomes data.”  
Mart Pearson, VP Europe for Cohera Medical, Inc. added: “We were very pleased that this series report on drain-free donor site closure with TissuGlu was selected for presentation at such a high-level meeting. Prof. Andree and his team at the SANA Clinic in Gerresheim have been very attentive to the patient perspective with regards to the post-surgical recovery period and it is exciting to have their experience discussed at this venue.” 

Snake venom is key ingredient in experimental drug for heart patients

An experimental antiplatelet drug has surprising bite. Based on a protein found in snake venom, the new drug prevented blood clotting in mice without causing excessive bleeding after an injury, according to research published Thursday in the journal Arteriosclerosis, Thrombosis and Vascular Biology. The drug has yet to be tested in humans.

Bleeding is a common side effect in the current crop of available antiplatelet drugs, which are usually prescribed for heart patients to prevent blood cells, called platelets, from clumping together and forming clots. Depending on where they occur, clots can lead to a stroke or heart attack.

“As a scientist, it is always intriguing to learn from our mother nature,” wrote Y. Jane Tseng, co-lead author of the study and a professor at the Genomics Center School of Pharmacy at National Taiwan University, in an email.

“There is a long history of using snake venom as a tool to study blood clotting mechanism,” Tseng said, adding that the only available antiplatelet drugs used for thrombosis — in which a clot occurs in a blood vessel and obstructs circulation — are also based on venom, though not the same one used in her study.

Tur-Fu Huang, co-lead author of the study and a professor at the Graduate Institute of Pharmacology at National Taiwan University, said some snake venoms are neurotoxic — poisonous to the brain — while others are hemorrhagic and “affect blood coagulation and platelet function profoundly.” The new research concentrated on venom that is hemorrhagic in nature.

In earlier work, Huang, Tseng and their colleagues found that trowaglerix from the venom of Tropidolaemus wagleri, commonly known as Wagler’s pit viper, latched onto glycoprotein VI, a protein that sits on the surface of platelets.

“Not every snake venom acts in similar mode on platelets,” Tseng said.

This attachment to glycoprotein VI is how trowaglerix stimulates platelets to form blood clots, the researchers learned. Platelets that are missing glycoprotein VI do not form blood clots and do not lead to severe bleeding.

If glycoprotein VI could be blocked, the research team hypothesized, would that prevent prolonged bleeding?

Putting this theory to the test, the researchers designed a molecule that could prevent clotting, and with added properties of trowaglerix, it did not cause severe bleeding. When this experimental drug was given to mice, the rodents showed slower blood clot formation, yet they also did not bleed longer than untreated mice, Tseng and her colleagues found.

“We successfully transformed trowaglerix into an anti-thrombotic agent,” said Huang, who noted that the experimental drug was both effective and safe. Still, it needs further testing in animals and humans, which will take some time.

In the meantime, he said, it can be modified and optimized “to a more potent and stable agent” with potential for use in patients. Ultimately, he and his colleagues hope their work could yield an entire class of effective antiplatelet drugs with limited side effects.

‘Of course there are safety issues’

Dr. Leslie Boyer, director of the VIPER Institute in Tucson, Arizona, said the new study “doesn’t automatically mean that you have a drug, because of course there are safety issues.”

“If they could find a very perfectly tuned molecule that a snake makes and give just the right dose,” Boyer said, it might be “of therapeutic benefit to certain people.”

“Venom contains many, many toxins. Even a single snake might have a 100 different types of venom molecules in their repertoire,” said Boyer, who was not involved in the new study. She added that even though the modest dose of venom delivered when a snake bites is “quite toxic.” But if you took that same poisonous venom, teased out the ingredients, scaled them down and used only a low dose, there are a lot of ingredients “that could be put to good use.”

Toxicologists don’t really distinguish one molecule as poisonous and another as benign, she said.

“It’s all a matter of dose,” Boyer said. “So a small dose of something might be a medicine, and a large dose becomes a poison.”

Snakes have venom for all kinds of reasons, she said, though the biggest reason, perhaps, is “to make lunch hold still.”

“A lot of snakes are relatively slow-moving creatures. They’re ambush predators or they only travel a short distance to get their prey,” Boyer said, noting that snakes “have one chance, one quick strike, to administer something that’s going to make very fast-moving prey, like a bird or a rodent, hold still — fall down and wait to be eaten.”

The molecules in snake venom, then, interact with the nervous system or with the cardiovascular system and represent “potential drugs” that might act on the nervous system to lessen pain or relax muscles, she said. The venom molecules that interact with the cardiovascular system, as Tseng, Huang and their co-authors show, “have the potential to be used for blood pressure problems or for heart rate situations, things like that,” Boyer said.

There are other toxins that have a direct effect on the tissues next to where the fang goes in that can digest proteins, which along with fat is what animals are made of, so “those molecules have all kinds of potential also,” she said. “For instance, breaking down specific proteins is something that might be useful not only for drugs but maybe for laundry detergent or things that remove stains. Maybe they’re good for recycling.”

But, caution is required, Boyer said: The reason we know anything about venom at all is that snake bites make people sick.

Friday, June 2, 2017

Hemostatic agents market is estimated to reach USD 8,347.9 Million by 2022

Surgery is a foundational component of health-care systems. Over 51 million hospital-based surgical procedures are performed annually worldwide. The effective management of bleeding to achieve hemostasis during surgical procedures is essential to promote positive outcomes. As surgical procedures evolve to be more refined and noninvasive, the utilization of fast acting biologically and synthetically derived hemostats, encompassing fibrin sealants, flowable gelatins and adhesives, is becoming increasingly prevalent. Some of the parameters for choosing a hemostatic agent includes efficiency, type of surgery, patient condition, need for quicker results, active bleeding tissue VS pooled blood sites and cost. Global hemostatic agents market is estimated to grow at a rate of 7.1% CAGR to reach $8,347.9m by 2022.

Currently, fibrin sealants are the most effective tissue adhesives used in surgeries. Additionally, the properties such as biocompatibility and biodegradability of this sealants are set to drive the growth of hemostatic agents market. Fibrin sealants are widely employed in various surgical specialties such as cardiovascular surgery, thoracic surgery, neurosurgery, plastic and reconstructive surgery, and dental surgery and others. Hemostasis is a complex method requiring the delicately coordinated activation of platelets as well as plasma clotting factors to form a platelet-fibrin clot. Hemostatic agents such as Thrombin Based Hemostats, Gelatin Based Hemostats, Collagen Based Hemostats and many more are used to control the flow of blood during a surgery or dressing an injury. These hemostatic agents are required in hospitals, surgery centers, nursing homes and other centers during the operations.

Cardiovascular surgery is the key treatment with regards to hemostatic agents market. Risk of cardiovascular diseases generally increases with the increase in age. Globally cardiovascular disease related deaths surged in developed nations including the U.S. and Europe where chronic diseases being the major contributor of death. Hemostatic agents are also considered and used majorly to improve clinical outcome, whereas aesthetics and cost effectiveness have less importance. The other surgeries where hemostats are utilized primarily include cosmetic, orthopedic, urological and arthroscopic surgeries. The rising cosmetic surgeries globally has been a one of the major driver for the growing usage of hemostats among the others segment.

Key Players in this Market Include: -

Johnson and Johnson Services Inc (U.S.)
B.Braun Melsungen AG (Germany)
C.R. Bard Incorporation (U.S.)
Mallinckrodt Plc (U.S.)
Integra Life Sciences Corporation (U.S.)
Americas held a major share in the market in 2016 whereas Asia-Pacific region is projected to witness the fastest growth during the forecast period. Global Hemostatic agents market is quite consolidated with key medical consumable and surgical technology players having significant presence. Frequent product launches, acquisitions and expansion are a few of the growth strategies the key players in the industry are adopting to increase their market share.